** THE EFFECT OF HYPOXIA ON HUMAN NEUTROPHILS **
In this study, the effects of Hypoxia on human Neutrophils were investigated in order to identify the possible involvement of inflammatory response in adverse prognosis of hypoxia-related disease, such as pulmonary hypertension and myocardial infarction. Primary cultures of human neutrophils were studied in both normal and hypoxia conditions. A gene expression profile of the neutrophils in both conditions were done after centain amounts of time in culture, and quantified using Affymetrix GeneChip HGU133 PLUS 2. The study was conducted on two separate samples.
This report aims to estimate gene expression levels, and analyse the results to identify the genes that are changing between the two conditions, defining the potential pathways that hypoxia may have altered in neutrophils.
** Data Analysis **
Workflow
Step 1: Load packages with data from Bioconductor, library(affy) - mas5, rma, library(puma)
Step 2: Load and read data, create affybatch. Annotate with pData.
Step 3: Analysis of gene expression data with different methods and normalisation techniques.
Create eset
Extract gene expression
First diagnostic using density() and boxplot()
Normalisation by log2 if required
Step 4: Diagnostics of the data with plotting techniques
MAPlot
boxplot
Step 5: Differential Expression Analysis
For
puma
, combine the data using an bayesian Hierarchical modelCheck the dimension and the
pData()
for the eset of the combined values. Calculate the FC and plot the data with a MA plot using the command ma.plot()MAPlot
use of
limma
for DE analysis. Remember the three core steps oflimma
Step 1: build the design contrast matrix
Step 2: fit the linear model
Step 3: calculate the p-values and FDRs with a empirical Bayes test
Step 6: Visualisation of Data with PCA
perform PCA in R using the command
prcomp()
It needs the traspose command
t()
since the input for theprcomp()
wants the genes in the columnsFor probabilistic PCA you can use
pumaPCA()
Step 7: Hierarchical clustering of DE (Differentially Expressed) genes
To perform this we need to activate a library called
gplots
. We will use the commandheatmap.2()
.We do clustering a the selected genes from our DE analysis this is to search for patterns in of differentially regulatend pathways.
Step 8: Functional/Pathway analysis of DE targets using PANTHER or DAVID
Step 1:
This step loads the affy package, which is part of the BioConductor project, allowing for data analysis and exploration of Affymetrix oligonucleotide array probe level data. It summarises the probe set intensities, forming one expression measure (data available for analysis) for each gene. The package includes plotting functions for the probe level data useful for quality control, making it useful in the initial analysis of the data, it includes plotting functions for the data that can be useful for quality control of data, RNA degradation assessments, normaliasation and background correction procedures. It also allows for probe level data to be converted to expression measures. In this project, MAS 5.0 and RMA are used for perform the analysis.
Step 2:
Set working directory
In order to load the data that is required, a working directory must be set, leading to where the data is saved.
The files that contain the data are saved in the .CEL format, indicating the files contain measured intensities and locations for an array that has been hybridised.
The data shows the size of the array is 1154x1164 (18kb), cdf maps each gene that is in the array (54675 genes), and there are 4 samples.
sample | |
---|---|
LPGMa.CEL | 1 |
LPGMb.CEL | 2 |
LPHa.CEL | 3 |
LPHb.CEL | 4 |
pData retrieves information on experimental phenotypes that are recorded.
Condition | Sample | |
---|---|---|
LPGMa.CEL | Normal | 1 |
LPGMb.CEL | Normal | 2 |
LPHa.CEL | Hypoxia | 1 |
LPHb.CEL | Hypoxia | 2 |
Step 3:
This step involves the analysis of gene expression data with different methods and normalisation techniques. The methods convert the probe level data to expression values, which is achieved through:
Reading in probe level data
Background correction
Normalization
Probe specific background correction
Summarising the probe set values into one expression measure
RMA and MAS 5.0 creates two different types of ExpressionSets, from which the gene expression values will be extracted.
LPGMa.CEL | LPGMb.CEL | LPHa.CEL | LPHb.CEL | |
---|---|---|---|---|
1007_s_at | 6.359706 | 6.378816 | 6.399439 | 6.320410 |
1053_at | 7.488801 | 7.490398 | 7.339287 | 7.136260 |
117_at | 10.880260 | 10.738160 | 11.348179 | 11.316371 |
121_at | 7.359978 | 7.344536 | 7.452264 | 7.372993 |
1255_g_at | 2.471620 | 2.503735 | 2.670402 | 2.575980 |
1294_at | 6.208576 | 6.346277 | 6.331029 | 6.551821 |
LPGMa.CEL | LPGMb.CEL | LPHa.CEL | LPHb.CEL | |
---|---|---|---|---|
1007_s_at | 428.46053 | 362.13667 | 437.20195 | 404.803198 |
1053_at | 604.36568 | 540.84643 | 549.49801 | 592.917234 |
117_at | 7722.59667 | 7774.66079 | 11815.21462 | 11637.983040 |
121_at | 461.12158 | 379.06718 | 470.19313 | 480.864624 |
1255_g_at | 41.02802 | 48.25334 | 72.33834 | 4.947423 |
1294_at | 246.59488 | 251.62389 | 293.92585 | 322.333187 |
LPGMa.CEL | LPGMb.CEL | LPHa.CEL | LPHb.CEL | |
---|---|---|---|---|
1007_s_at | 8.743019 | 8.500390 | 8.772156 | 8.661077 |
1053_at | 9.239278 | 9.079075 | 9.101970 | 9.211687 |
117_at | 12.914870 | 12.924564 | 13.528358 | 13.506553 |
121_at | 8.849003 | 8.566310 | 8.877110 | 8.909487 |
1255_g_at | 5.358538 | 5.592557 | 6.176689 | 2.306677 |
1294_at | 7.945999 | 7.975125 | 8.199308 | 8.332409 |
Expression values for mas5 and rma are extracted and the first diagnostics performed on the data, using density() and boxplot(). Initial mas5 estimation showed the data was difficult to read due to the large values of the outliers, therefore a log2 transformation was performed, to change the scale and make the plots more readable. The transformation also eliminated much of the negative values. No transformation or normalisation was required however, as the medians are aligned, with no negative outliers. Therefore, further analysis is continued with the use of rma extracted expressions.
puma (Propagating Uncertainty in Microarray Analysis) is another bioconductor package. Microarrays measure the expression level of thousands of genes simultaneously, therefore there are many significant soutces of uncertainties associated with it; these uncertainties must be considered to accurately infer from the data. Earlier methods used (mas5 and rma) only provide single point estimates that summarises the target concentration. By using probabilistic models such as puma for probe-level analysis, it is possible to associate gene expression levels with credibility intervals that quantify the measurement uncentainty associated with the estimate of target concentration with a sample. puma performs analysis through:
Calculation of expression levels and confidence measures for those levels from raw .CEL data
Combine uncertainty information from replicated arrays
Determine differential expression between conditions, or between more complex contrasts such as interaction terms
Cluster data taking the expression level uncertainty into account
Perform a noise-propagation version of principal compinent analysis (PCA)
LPGMa.CEL | LPGMb.CEL | LPHa.CEL | LPHb.CEL | |
---|---|---|---|---|
1007_s_at | 5.902316 | 5.6103537 | 5.6174054 | 5.737430 |
1053_at | 6.626212 | 6.6790712 | 6.3627049 | 6.180460 |
117_at | 10.170737 | 10.1217316 | 10.6852717 | 10.553831 |
121_at | 5.211771 | 4.8356632 | 5.5315978 | 5.400501 |
1255_g_at | -1.389828 | 0.2041968 | 0.2107774 | -1.592713 |
1294_at | 5.458750 | 5.9264062 | 5.8934533 | 6.153923 |
LPGMa.CEL | LPGMb.CEL | LPHa.CEL | LPHb.CEL | |
---|---|---|---|---|
1007_s_at | 5.902316 | 5.6103537 | 5.6174054 | 5.737430 |
1053_at | 6.626212 | 6.6790712 | 6.3627049 | 6.180460 |
117_at | 10.170737 | 10.1217316 | 10.6852717 | 10.553831 |
121_at | 5.211771 | 4.8356632 | 5.5315978 | 5.400501 |
1255_g_at | -1.389828 | 0.2041968 | 0.2107774 | -1.592713 |
1294_at | 5.458750 | 5.9264062 | 5.8934533 | 6.153923 |
After performing pumaNormalize() on the data, the first diagnostic tests showed that there is no difference to the data prior to normalisation, therefore indicating that the pumadata is already normalised.
Although the data is shown to be normalized, and the medians are aligned, it can also be seem from the boxplot that there is a large number of negative outliers, therefore the negative gene expression values are set to zero, to further normalise the data.
LPGMa.CEL | LPGMb.CEL | LPHa.CEL | LPHb.CEL | |
---|---|---|---|---|
1007_s_at | 5.902316 | 5.6103537 | 5.6174054 | 5.737430 |
1053_at | 6.626212 | 6.6790712 | 6.3627049 | 6.180460 |
117_at | 10.170737 | 10.1217316 | 10.6852717 | 10.553831 |
121_at | 5.211771 | 4.8356632 | 5.5315978 | 5.400501 |
1255_g_at | 0.000000 | 0.2041968 | 0.2107774 | 0.000000 |
1294_at | 5.458750 | 5.9264062 | 5.8934533 | 6.153923 |
Boxplots show the differences in probe intensity behaviour between arrays. Boxplots are useful in the visualisation of data for first diagnostics, ensuring all the samples are comparable. Box plots show are able to illustrate:
Median
Upper Quartile
Lower Quartile
Range
Individual extreme values (Outliers)
The boxplots above show that gene expression extracted using rma does not need to be normalised as the medians are aligned, and no negative outliers. The mas5 boxplot showed the data must be log2 transformed in order for comparison to be possible. For puma, the results needed to be normalised due to the high number of negative outliers present, although the medians are aligned.
All three analysis techniques showed a similar range of values following normalisation.
In MA plots, each Affymetrix marray is compared to a pseudo-array, which consist of the median intensity of each probe over all arrays, the plot shows to what extent the variability in expression depends on the expression level. M is the difference between the intensity of a probe on the array and the median intensity of that probe over all arrays A is the average intensity of a probe on that array and the median intensity of that probe over all arrays.
The cloud of data points in the MA plot is centered around M=0, based on the assumption that the majority of the genes are not differentially expressed, an the number of upregulated genes is similar to the number of downregulated genes.
From the MA plots above, it can be deduced that there appears to be a greater number of downregulated genes in neutrophils under hypoxia conditions than in normal conditions.
Step 5:
- 'affybatch.hypoxia'
- 'e_mas5'
- 'e_puma'
- 'e_puma_normd'
- 'e_rma'
- 'eset_mas5'
- 'eset_puma'
- 'eset_puma_comb'
- 'eset_puma_normd'
- 'eset_rma'
- 'hypoxia_filenames'
- 'i'
- 'log2e_mas5'
- 'y'
Condition | Sample | |
---|---|---|
Hypoxia.1 | Hypoxia | 1 |
Normal.1 | Normal | 1 |
Hypoxia.2 | Hypoxia | 2 |
Normal.2 | Normal | 2 |
- Features
- 54675
- Samples
- 4
Hypoxia-Normal 1 | Hypoxia-Normal 2 | |
---|---|---|
1007_s_at | -0.0003167666 | 0.0009128018 |
1053_at | 0.0007166274 | -0.0002780249 |
117_at | 0.0032436276 | 0.0011207505 |
121_at | 0.0001154092 | 0.0002085455 |
1255_g_at | 0.0000000000 | 0.0000000000 |
1294_at | -0.0019379157 | -0.0020818635 |
Hypoxia-Normal 1 | Hypoxia-Normal 2 | |
---|---|---|
1007_s_at | -0.03973322 | 0.05840595 |
1053_at | 0.14951411 | 0.35413809 |
117_at | -0.46791889 | -0.57821119 |
121_at | -0.09228612 | -0.02845722 |
1255_g_at | -0.19878260 | -0.07224494 |
1294_at | -0.12245352 | -0.20554369 |
- H1
- N1
- H2
- N2
sampleNames.eset_puma_comb. | groups |
---|---|
Hypoxia.1 | H1 |
Normal.1 | N1 |
Hypoxia.2 | H2 |
Normal.2 | N2 |
Normal | Hypoxia | |
---|---|---|
1 | 0 | 1 |
2 | 0 | 1 |
3 | 1 | 0 |
4 | 1 | 0 |
Normal | Hypoxia | |
---|---|---|
Normal | 1 | 0 |
Hypoxia | 0 | 1 |
logFC | AveExpr | t | P.Value | adj.P.Val | B | |
---|---|---|---|---|---|---|
200958_s_at | 13.16920 | 13.11567 | 124.3121 | 4.891234e-07 | 2.954137e-05 | 5.351285 |
204006_s_at | 12.87494 | 12.61830 | 123.9542 | 4.936824e-07 | 2.954137e-05 | 5.350019 |
200748_s_at | 13.33368 | 13.34257 | 122.0398 | 5.190456e-07 | 2.954137e-05 | 5.343069 |
211919_s_at | 12.99841 | 12.80683 | 121.8356 | 5.218509e-07 | 2.954137e-05 | 5.342310 |
211742_s_at | 12.62507 | 12.33153 | 121.0488 | 5.328459e-07 | 2.954137e-05 | 5.339351 |
1555745_a_at | 12.85586 | 12.53620 | 121.0256 | 5.331751e-07 | 2.954137e-05 | 5.339263 |
AFFX-HSAC07/X00351_3_at | 12.84239 | 12.95069 | 120.9210 | 5.346613e-07 | 2.954137e-05 | 5.338865 |
AFFX-hum_alu_at | 13.11747 | 13.12849 | 120.9017 | 5.349360e-07 | 2.954137e-05 | 5.338792 |
212560_at | 12.62891 | 12.38139 | 120.4412 | 5.415465e-07 | 2.954137e-05 | 5.337029 |
217028_at | 13.12695 | 12.97323 | 120.2231 | 5.447149e-07 | 2.954137e-05 | 5.336188 |
208980_s_at | 12.53417 | 12.55008 | 120.1028 | 5.464738e-07 | 2.954137e-05 | 5.335722 |
202727_s_at | 12.53732 | 12.55374 | 119.9873 | 5.481680e-07 | 2.954137e-05 | 5.335273 |
202917_s_at | 13.44072 | 13.46929 | 119.8412 | 5.503220e-07 | 2.954137e-05 | 5.334704 |
200801_x_at | 12.79446 | 12.86409 | 119.7931 | 5.510328e-07 | 2.954137e-05 | 5.334517 |
200668_s_at | 12.48924 | 12.47371 | 119.5855 | 5.541183e-07 | 2.954137e-05 | 5.333703 |
201368_at | 12.71576 | 12.42925 | 119.5836 | 5.541462e-07 | 2.954137e-05 | 5.333696 |
212587_s_at | 12.65005 | 12.59432 | 119.5826 | 5.541612e-07 | 2.954137e-05 | 5.333692 |
202388_at | 12.95929 | 12.60095 | 119.3217 | 5.580716e-07 | 2.954137e-05 | 5.332665 |
200704_at | 12.84004 | 12.89974 | 119.2973 | 5.584377e-07 | 2.954137e-05 | 5.332569 |
200794_x_at | 12.66494 | 12.71327 | 119.1220 | 5.610873e-07 | 2.954137e-05 | 5.331874 |
215952_s_at | 12.73163 | 12.62020 | 118.9827 | 5.632039e-07 | 2.954137e-05 | 5.331321 |
209201_x_at | 12.96794 | 12.76079 | 118.9804 | 5.632398e-07 | 2.954137e-05 | 5.331311 |
AFFX-HSAC07/X00351_5_at | 12.36732 | 12.55121 | 118.8585 | 5.651011e-07 | 2.954137e-05 | 5.330826 |
201721_s_at | 13.02248 | 13.02379 | 118.8531 | 5.651844e-07 | 2.954137e-05 | 5.330804 |
224765_at | 12.35501 | 11.72387 | 118.6302 | 5.686084e-07 | 2.954137e-05 | 5.329912 |
228754_at | 12.34079 | 12.06019 | 118.5799 | 5.693850e-07 | 2.954137e-05 | 5.329710 |
AFFX-HSAC07/X00351_M_at | 12.53094 | 12.68500 | 118.5455 | 5.699171e-07 | 2.954137e-05 | 5.329572 |
208679_s_at | 12.82208 | 12.76857 | 118.4661 | 5.711483e-07 | 2.954137e-05 | 5.329252 |
204122_at | 12.78061 | 12.81913 | 118.3847 | 5.724132e-07 | 2.954137e-05 | 5.328923 |
211296_x_at | 12.73171 | 12.73269 | 118.3529 | 5.729075e-07 | 2.954137e-05 | 5.328795 |
⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ |
71 | 12.16112 | 11.66354 | 115.4135 | 6.212097e-07 | 2.954137e-05 | 5.316500 |
72 | 12.60173 | 12.61777 | 115.4121 | 6.212343e-07 | 2.954137e-05 | 5.316493 |
73 | 12.82313 | 13.02037 | 115.2926 | 6.233099e-07 | 2.954137e-05 | 5.315975 |
74 | 12.35619 | 11.88091 | 115.2806 | 6.235184e-07 | 2.954137e-05 | 5.315923 |
75 | 12.01287 | 11.82985 | 115.2349 | 6.243133e-07 | 2.954137e-05 | 5.315725 |
76 | 12.08655 | 11.76656 | 115.1775 | 6.253161e-07 | 2.954137e-05 | 5.315475 |
77 | 12.08300 | 11.74270 | 115.1515 | 6.257710e-07 | 2.954137e-05 | 5.315361 |
78 | 13.05271 | 13.04967 | 115.0145 | 6.281731e-07 | 2.954137e-05 | 5.314763 |
79 | 12.08619 | 11.89104 | 114.9890 | 6.286219e-07 | 2.954137e-05 | 5.314652 |
80 | 12.63099 | 12.73537 | 114.9662 | 6.290222e-07 | 2.954137e-05 | 5.314552 |
81 | 12.04174 | 12.15283 | 114.9463 | 6.293735e-07 | 2.954137e-05 | 5.314465 |
82 | 12.28123 | 12.27198 | 114.9459 | 6.293805e-07 | 2.954137e-05 | 5.314463 |
83 | 12.36272 | 12.52576 | 114.9123 | 6.299725e-07 | 2.954137e-05 | 5.314316 |
84 | 12.09863 | 11.61412 | 114.8484 | 6.311019e-07 | 2.954137e-05 | 5.314035 |
85 | 12.11993 | 12.16425 | 114.7207 | 6.333660e-07 | 2.954137e-05 | 5.313474 |
86 | 12.14712 | 11.62236 | 114.6764 | 6.341531e-07 | 2.954137e-05 | 5.313279 |
87 | 12.16596 | 12.04887 | 114.6760 | 6.341598e-07 | 2.954137e-05 | 5.313277 |
88 | 12.07946 | 12.06161 | 114.6299 | 6.349816e-07 | 2.954137e-05 | 5.313074 |
89 | 11.99899 | 12.09922 | 114.6182 | 6.351897e-07 | 2.954137e-05 | 5.313022 |
90 | 11.92110 | 11.82842 | 114.6063 | 6.354027e-07 | 2.954137e-05 | 5.312970 |
91 | 12.19644 | 12.19601 | 114.5656 | 6.361297e-07 | 2.954137e-05 | 5.312790 |
92 | 12.22030 | 12.22629 | 114.5647 | 6.361456e-07 | 2.954137e-05 | 5.312786 |
93 | 12.28066 | 12.24067 | 114.5480 | 6.364439e-07 | 2.954137e-05 | 5.312712 |
94 | 12.13352 | 12.16809 | 114.5474 | 6.364545e-07 | 2.954137e-05 | 5.312709 |
95 | 12.04900 | 11.96460 | 114.5259 | 6.368395e-07 | 2.954137e-05 | 5.312614 |
96 | 12.27975 | 12.26686 | 114.4355 | 6.384589e-07 | 2.954137e-05 | 5.312214 |
97 | 12.19763 | 12.27570 | 114.4078 | 6.389574e-07 | 2.954137e-05 | 5.312091 |
98 | 12.86782 | 13.04416 | 114.4035 | 6.390343e-07 | 2.954137e-05 | 5.312072 |
99 | 12.04219 | 11.50384 | 114.3701 | 6.396356e-07 | 2.954137e-05 | 5.311924 |
100 | 12.72957 | 12.72944 | 114.3418 | 6.401459e-07 | 2.954137e-05 | 5.311798 |
Limma is a package for differential expression analysis of data arising from microarray experiments. A linear model is fit to the expression data for each gene. Empirical Beyes (a shrinkage method) is used to borrow information across genes making the analyses stable. Linear models are used to analyse designed microarray experiments, allowing for very general experiments to be analysed easily. Two matrices need to be specified. The design matrix provides a representation of the different RNA targets which have been hybridized to the arrays. The contrast matrix allows the coefficients designed by the design matrix to be combined into contrasts of interest. Each contrast corresponds to a comparison of interest between the RNA targets.
The Venn Diagram shows that 3761 genes and 3390 genes were expressed in only normal and only hypoxia conditions, respectively. 35170 genes were expressed in both normal and hypoxia conditions.
- 100
- 6
- '200958_s_at'
- '204006_s_at'
- '200748_s_at'
- '211919_s_at'
- '211742_s_at'
- '1555745_a_at'
- 'AFFX-HSAC07/X00351_3_at'
- 'AFFX-hum_alu_at'
- '212560_at'
- '217028_at'
- '208980_s_at'
- '202727_s_at'
- '202917_s_at'
- '200801_x_at'
- '200668_s_at'
- '201368_at'
- '212587_s_at'
- '202388_at'
- '200704_at'
- '200794_x_at'
- '215952_s_at'
- '209201_x_at'
- 'AFFX-HSAC07/X00351_5_at'
- '201721_s_at'
- '224765_at'
- '228754_at'
- 'AFFX-HSAC07/X00351_M_at'
- '208679_s_at'
- '204122_at'
- '211296_x_at'
- '202391_at'
- '207238_s_at'
- '211940_x_at'
- '208763_s_at'
- '225414_at'
- '203535_at'
- '207008_at'
- '211911_x_at'
- '1555756_a_at'
- '201858_s_at'
- '204774_at'
- '1553588_at'
- '213828_x_at'
- '228846_at'
- '209732_at'
- '210774_s_at'
- '211997_x_at'
- '224373_s_at'
- '216231_s_at'
- '208616_s_at'
- '204959_at'
- '213702_x_at'
- '202902_s_at'
- '208718_at'
- '220990_s_at'
- '225364_at'
- '216438_s_at'
- '201210_at'
- '200774_at'
- '218614_at'
- '224761_at'
- '226810_at'
- '208783_s_at'
- '200059_s_at'
- '208788_at'
- '224583_at'
- '205922_at'
- 'AFFX-HUMGAPDH/M33197_3_at'
- '232617_at'
- '218205_s_at'
- '226979_at'
- '211676_s_at'
- '211956_s_at'
- '200921_s_at'
- '209083_at'
- '203509_at'
- '221059_s_at'
- '212788_x_at'
- '207988_s_at'
- '200706_s_at'
- '202833_s_at'
- '204563_at'
- '201779_s_at'
- '200920_s_at'
- '200729_s_at'
- '209112_at'
- '217983_s_at'
- '224372_at'
- '208736_at'
- '224451_x_at'
- '1553570_x_at'
- '217967_s_at'
- '204351_at'
- '209933_s_at'
- '201862_s_at'
- '200904_at'
- '205568_at'
- '211506_s_at'
- '213241_at'
- '209949_at'
PROBEID | SYMBOL | GENENAME |
---|---|---|
200958_s_at | SDCBP | syndecan binding protein (syntenin) |
204006_s_at | FCGR3B | Fc fragment of IgG, low affinity IIIb, receptor (CD16b) |
204006_s_at | FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) |
200748_s_at | FTH1 | ferritin, heavy polypeptide 1 |
211919_s_at | CXCR4 | chemokine (C-X-C motif) receptor 4 |
211742_s_at | EVI2B | ecotropic viral integration site 2B |
1555745_a_at | LYZ | lysozyme |
AFFX-HSAC07/X00351_3_at | ACTB | actin, beta |
AFFX-hum_alu_at | NA | NA |
212560_at | SORL1 | sortilin-related receptor, L(DLR class) A repeats containing |
217028_at | CXCR4 | chemokine (C-X-C motif) receptor 4 |
208980_s_at | UBC | ubiquitin C |
202727_s_at | IFNGR1 | interferon gamma receptor 1 |
202917_s_at | S100A8 | S100 calcium binding protein A8 |
200801_x_at | ACTB | actin, beta |
200668_s_at | UBE2D3 | ubiquitin-conjugating enzyme E2D 3 |
201368_at | ZFP36L2 | ZFP36 ring finger protein-like 2 |
212587_s_at | PTPRC | protein tyrosine phosphatase, receptor type, C |
202388_at | RGS2 | regulator of G-protein signaling 2 |
200704_at | LITAF | lipopolysaccharide-induced TNF factor |
200794_x_at | DAZAP2 | DAZ associated protein 2 |
215952_s_at | OAZ1 | ornithine decarboxylase antizyme 1 |
209201_x_at | CXCR4 | chemokine (C-X-C motif) receptor 4 |
AFFX-HSAC07/X00351_5_at | ACTB | actin, beta |
201721_s_at | LAPTM5 | lysosomal protein transmembrane 5 |
224765_at | MSL1 | male-specific lethal 1 homolog (Drosophila) |
228754_at | SLC6A6 | solute carrier family 6 (neurotransmitter transporter), member 6 |
AFFX-HSAC07/X00351_M_at | ACTB | actin, beta |
208679_s_at | ARPC2 | actin related protein 2/3 complex, subunit 2, 34kDa |
204122_at | TYROBP | TYRO protein tyrosine kinase binding protein |
⋮ | ⋮ | ⋮ |
211676_s_at | IFNGR1 | interferon gamma receptor 1 |
211956_s_at | EIF1 | eukaryotic translation initiation factor 1 |
200921_s_at | BTG1 | B-cell translocation gene 1, anti-proliferative |
209083_at | CORO1A | coronin, actin binding protein, 1A |
203509_at | SORL1 | sortilin-related receptor, L(DLR class) A repeats containing |
221059_s_at | CHST6 | carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 |
221059_s_at | COTL1 | coactosin-like F-actin binding protein 1 |
212788_x_at | FTL | ferritin, light polypeptide |
207988_s_at | ARPC2 | actin related protein 2/3 complex, subunit 2, 34kDa |
200706_s_at | LITAF | lipopolysaccharide-induced TNF factor |
202833_s_at | SERPINA1 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 |
204563_at | SELL | selectin L |
201779_s_at | RNF13 | ring finger protein 13 |
200920_s_at | BTG1 | B-cell translocation gene 1, anti-proliferative |
200729_s_at | ACTR2 | ARP2 actin-related protein 2 homolog (yeast) |
209112_at | CDKN1B | cyclin-dependent kinase inhibitor 1B (p27, Kip1) |
217983_s_at | RNASET2 | ribonuclease T2 |
224372_at | ND4 | NADH dehydrogenase, subunit 4 (complex I) |
208736_at | ARPC3 | actin related protein 2/3 complex, subunit 3, 21kDa |
224451_x_at | ARHGAP9 | Rho GTPase activating protein 9 |
1553570_x_at | COX2 | cytochrome c oxidase subunit II |
217967_s_at | FAM129A | family with sequence similarity 129, member A |
204351_at | S100P | S100 calcium binding protein P |
209933_s_at | CD300A | CD300a molecule |
201862_s_at | LRRFIP1 | leucine rich repeat (in FLII) interacting protein 1 |
200904_at | HLA-E | major histocompatibility complex, class I, E |
205568_at | AQP9 | aquaporin 9 |
211506_s_at | CXCL8 | chemokine (C-X-C motif) ligand 8 |
213241_at | PLXNC1 | plexin C1 |
209949_at | NCF2 | neutrophil cytosolic factor 2 |
- 'SDCBP'
- 'FCGR3B'
- 'FCGR3A'
- 'FTH1'
- 'CXCR4'
- 'EVI2B'
- 'LYZ'
- 'ACTB'
- 'NA'
- 'SORL1'
- 'CXCR4'
- 'UBC'
- 'IFNGR1'
- 'S100A8'
- 'ACTB'
- 'UBE2D3'
- 'ZFP36L2'
- 'PTPRC'
- 'RGS2'
- 'LITAF'
- 'DAZAP2'
- 'OAZ1'
- 'CXCR4'
- 'ACTB'
- 'LAPTM5'
- 'MSL1'
- 'SLC6A6'
- 'ACTB'
- 'ARPC2'
- 'TYROBP'
- 'UBC'
- 'BASP1'
- 'PTPRC'
- 'H3F3A'
- 'H3F3B'
- 'H3F3AP4'
- 'TSC22D3'
- 'RNF149'
- 'S100A9'
- 'CXCR2'
- 'HLA-B'
- 'CLEC7A'
- 'SRGN'
- 'EVI2A'
- 'ND3'
- 'SH3KBP1'
- 'H3F3A'
- 'H3F3B'
- 'H3F3AP4'
- 'MXD1'
- 'CLEC2B'
- 'NCOA4'
- 'H3F3B'
- 'H3F3A'
- 'MIR4738'
- 'ND4'
- 'B2M'
- 'PTP4A2'
- 'MNDA'
- 'ASAH1'
- 'CTSS'
- 'DDX17'
- 'VMP1'
- 'MIR21'
- 'STK4'
- 'TMSB4X'
- 'DDX3X'
- 'FAM120A'
- 'KIAA1551'
- 'GNA13'
- 'OGFRL1'
- 'CD46'
- 'RHOA'
- 'ELOVL5'
- 'COTL1'
- 'VNN2'
- 'GAPDH'
- 'CTSS'
- 'MKNK2'
- 'MAP3K2'
- 'IFNGR1'
- 'EIF1'
- 'BTG1'
- 'CORO1A'
- 'SORL1'
- 'CHST6'
- 'COTL1'
- 'FTL'
- 'ARPC2'
- 'LITAF'
- 'SERPINA1'
- 'SELL'
- 'RNF13'
- 'BTG1'
- 'ACTR2'
- 'CDKN1B'
- 'RNASET2'
- 'ND4'
- 'ARPC3'
- 'ARHGAP9'
- 'COX2'
- 'FAM129A'
- 'S100P'
- 'CD300A'
- 'LRRFIP1'
- 'HLA-E'
- 'AQP9'
- 'CXCL8'
- 'PLXNC1'
- 'NCF2'
- 'DEGenesSYMBOL.txt'
- 'eset_puma.RDA'
- 'eset_pumacomb.RDA'
- 'LPGMa.CEL'
- 'LPGMb.CEL'
- 'LPHa.CEL'
- 'LPHb.CEL'
- 'PANTHER_Pathway.png'
- 'pantherChart.txt'
- 'pantherGeneList.txt'
- 'pumaDERes_FCs.csv'
- 'pumaDERes_statistics.csv'
- 'SYMBOL.txt'
X | Normal.1_vs_Hypoxia.1 | Hypoxia.2_vs_Hypoxia.1 | Normal.2_vs_Normal.1 | Normal.2_vs_Hypoxia.2 | Condition_Hypoxia_vs_Normal | Sample_1_vs_2 | Int__Condition_Hypoxia.Normal_vs_Sample_1.2 |
---|---|---|---|---|---|---|---|
1007_s_at | 0.5113750 | 0.5040763 | 0.4882552 | 0.4955539 | 0.4975498 | 0.5027118 | 0.4944060 |
1053_at | 0.5164213 | 0.4895519 | 0.5040539 | 0.5308981 | 0.4832624 | 0.5022611 | 0.5051275 |
117_at | 0.4082059 | 0.4761349 | 0.4917497 | 0.4234843 | 0.5597413 | 0.5113582 | 0.5055253 |
121_at | 0.4965747 | 0.4985910 | 0.4974539 | 0.4954377 | 0.5028241 | 0.5013983 | 0.4995980 |
1255_g_at | 0.4965998 | 0.4963111 | 0.5034108 | 0.5036996 | 0.4998941 | 0.5000983 | 0.5025101 |
1294_at | 0.4807838 | 0.5198114 | 0.5212816 | 0.4822544 | 0.5130704 | 0.4854682 | 0.5005205 |
probeid | PPLR_N1vsH1 | PPLR_N2vsH2 |
---|---|---|
1007_s_at | 0.5113750 | 0.4955539 |
1053_at | 0.5164213 | 0.5308981 |
117_at | 0.4082059 | 0.4234843 |
121_at | 0.4965747 | 0.4954377 |
1255_g_at | 0.4965998 | 0.5036996 |
1294_at | 0.4807838 | 0.4822544 |
1316_at | 0.5027632 | 0.4971939 |
1320_at | 0.4974770 | 0.5011232 |
1405_i_at | 0.4949343 | 0.4911106 |
1431_at | 0.4815598 | 0.5103977 |
1438_at | 0.5009881 | 0.5005768 |
1487_at | 0.5521465 | 0.5394558 |
1494_f_at | 0.5036250 | 0.4874812 |
1552256_a_at | 0.4859761 | 0.5094893 |
1552257_a_at | 0.5269255 | 0.5426862 |
1552258_at | 0.5296864 | 0.5360022 |
1552261_at | 0.5024123 | 0.4974071 |
1552263_at | 0.5002512 | 0.5120329 |
1552264_a_at | 0.5087401 | 0.5142300 |
1552266_at | 0.4986212 | 0.5178322 |
1552269_at | 0.5007328 | 0.5008457 |
1552271_at | 0.5004264 | 0.5022765 |
1552272_a_at | 0.4978715 | 0.4888625 |
1552274_at | 0.9742525 | 0.9869562 |
1552275_s_at | 0.9382355 | 0.9633200 |
1552276_a_at | 0.5002337 | 0.5004873 |
1552277_a_at | 0.5154551 | 0.5125756 |
1552278_a_at | 0.4979116 | 0.4996785 |
1552279_a_at | 0.4968687 | 0.4988454 |
1552280_at | 0.5000570 | 0.4988962 |
⋮ | ⋮ | ⋮ |
AFFX-PheX-3_at | 6.383827e-20 | 2.273321e-19 |
AFFX-PheX-5_at | 4.565683e-10 | 4.361088e-10 |
AFFX-PheX-M_at | 1.048477e-09 | 1.116457e-09 |
AFFX-r2-Bs-dap-3_at | 9.091292e-10 | 4.329772e-10 |
AFFX-r2-Bs-dap-5_at | 9.638324e-14 | 1.339950e-13 |
AFFX-r2-Bs-dap-M_at | 8.537546e-08 | 1.068900e-07 |
AFFX-r2-Bs-lys-3_at | 1.101316e-17 | 2.225752e-17 |
AFFX-r2-Bs-lys-5_at | 3.508264e-27 | 1.746063e-27 |
AFFX-r2-Bs-lys-M_at | 1.291064e-21 | 1.064751e-21 |
AFFX-r2-Bs-phe-3_at | 5.069334e-23 | 1.557718e-22 |
AFFX-r2-Bs-phe-5_at | 2.727829e-19 | 8.052990e-19 |
AFFX-r2-Bs-phe-M_at | 6.153183e-12 | 5.725746e-12 |
AFFX-r2-Bs-thr-3_s_at | 2.039883e-20 | 5.979694e-20 |
AFFX-r2-Bs-thr-5_s_at | 9.929500e-17 | 1.425241e-16 |
AFFX-r2-Bs-thr-M_s_at | 2.017511e-20 | 4.427426e-19 |
AFFX-r2-Ec-bioB-3_at | 5.074861e-01 | 5.188246e-01 |
AFFX-r2-Ec-bioB-5_at | 4.782735e-01 | 4.845650e-01 |
AFFX-r2-Ec-bioB-M_at | 4.750756e-01 | 5.299473e-01 |
AFFX-r2-Ec-bioC-3_at | 4.848563e-01 | 5.102748e-01 |
AFFX-r2-Ec-bioC-5_at | 4.846223e-01 | 5.212988e-01 |
AFFX-r2-Ec-bioD-3_at | 4.914816e-01 | 5.154334e-01 |
AFFX-r2-Ec-bioD-5_at | 4.877219e-01 | 5.165479e-01 |
AFFX-r2-P1-cre-3_at | 4.936170e-01 | 5.089681e-01 |
AFFX-r2-P1-cre-5_at | 4.963582e-01 | 5.091534e-01 |
AFFX-ThrX-3_at | 1.478307e-11 | 1.845208e-11 |
AFFX-ThrX-5_at | 3.374282e-01 | 3.317903e-01 |
AFFX-ThrX-M_at | 2.961146e-21 | 1.959100e-21 |
AFFX-TrpnX-3_at | 4.753222e-01 | 5.152153e-01 |
AFFX-TrpnX-5_at | 4.894762e-01 | 4.862144e-01 |
AFFX-TrpnX-M_at | 4.999410e-01 | 5.024540e-01 |
X | Normal.1_vs_Hypoxia.1 | Hypoxia.2_vs_Hypoxia.1 | Normal.2_vs_Normal.1 | Normal.2_vs_Hypoxia.2 | Condition_Hypoxia_vs_Normal | Sample_1_vs_2 | Int__Condition_Hypoxia.Normal_vs_Sample_1.2 |
---|---|---|---|---|---|---|---|
1007_s_at | 0.0008676691 | 0.0003108934 | -0.0008958805 | -0.0003391048 | -2.642822e-04 | 2.924935e-04 | -6.033869e-04 |
1053_at | 0.0011140228 | -0.0007086750 | 0.0002749431 | 0.0020976409 | -1.605832e-03 | 2.168660e-04 | 4.918090e-04 |
117_at | -0.0125714683 | -0.0032412178 | -0.0011199112 | -0.0104501617 | 1.151082e-02 | 2.180565e-03 | 1.060653e-03 |
121_at | -0.0002734692 | -0.0001124929 | -0.0002032746 | -0.0003642509 | 3.188601e-04 | 1.578838e-04 | -4.539084e-05 |
1255_g_at | -0.0001363636 | -0.0001479422 | 0.0001367911 | 0.0001483697 | -6.003047e-06 | 5.575531e-06 | 1.423666e-04 |
1294_at | -0.0018486011 | 0.0019059397 | 0.0020474700 | -0.0017070709 | 1.777836e-03 | -1.976705e-03 | 7.076513e-05 |
PROBEID | SYMBOL | GENENAME | |
---|---|---|---|
1 | 1007_s_at | DDR1 | discoidin domain receptor tyrosine kinase 1 |
2 | 1007_s_at | MIR4640 | microRNA 4640 |
3 | 1053_at | RFC2 | replication factor C (activator 1) 2, 40kDa |
5 | 121_at | PAX8 | paired box 8 |
6 | 1255_g_at | GUCA1A | guanylate cyclase activator 1A (retina) |
7 | 1294_at | UBA7 | ubiquitin-like modifier activating enzyme 7 |
8 | 1294_at | MIR5193 | microRNA 5193 |
9 | 1316_at | THRA | thyroid hormone receptor, alpha |
10 | 1320_at | PTPN21 | protein tyrosine phosphatase, non-receptor type 21 |
11 | 1405_i_at | CCL5 | chemokine (C-C motif) ligand 5 |
12 | 1431_at | CYP2E1 | cytochrome P450, family 2, subfamily E, polypeptide 1 |
13 | 1438_at | EPHB3 | EPH receptor B3 |
14 | 1487_at | ESRRA | estrogen-related receptor alpha |
15 | 1494_f_at | CYP2A6 | cytochrome P450, family 2, subfamily A, polypeptide 6 |
16 | 1552256_a_at | SCARB1 | scavenger receptor class B, member 1 |
18 | 1552258_at | LINC00152 | long intergenic non-protein coding RNA 152 |
19 | 1552261_at | WFDC2 | WAP four-disulfide core domain 2 |
20 | 1552263_at | MAPK1 | mitogen-activated protein kinase 1 |
21 | 1552264_a_at | MAPK1 | mitogen-activated protein kinase 1 |
22 | 1552266_at | ADAM32 | ADAM metallopeptidase domain 32 |
24 | 1552271_at | PRR22 | proline rich 22 |
25 | 1552272_a_at | PRR22 | proline rich 22 |
26 | 1552274_at | PXK | PX domain containing serine/threonine kinase |
27 | 1552275_s_at | PXK | PX domain containing serine/threonine kinase |
28 | 1552276_a_at | VPS18 | vacuolar protein sorting 18 homolog (S. cerevisiae) |
29 | 1552277_a_at | MSANTD3 | Myb/SANT-like DNA-binding domain containing 3 |
30 | 1552278_a_at | SLC46A1 | solute carrier family 46 (folate transporter), member 1 |
31 | 1552279_a_at | SLC46A1 | solute carrier family 46 (folate transporter), member 1 |
32 | 1552280_at | TIMD4 | T-cell immunoglobulin and mucin domain containing 4 |
33 | 1552281_at | SLC39A5 | solute carrier family 39 (zinc transporter), member 5 |
⋮ | ⋮ | ⋮ | ⋮ |
899 | 1553462_at | NA | NA |
900 | 1553464_at | FLJ40288 | uncharacterized FLJ40288 |
901 | 1553465_a_at | CES5A | carboxylesterase 5A |
902 | 1553466_at | CFAP47 | cilia and flagella associated protein 47 |
903 | 1553467_at | DCAF8L2 | DDB1 and CUL4 associated factor 8-like 2 |
904 | 1553467_at | FLJ32742 | uncharacterized locus FLJ32742 |
905 | 1553467_at | LOC101928481 | uncharacterized LOC101928481 |
906 | 1553468_at | HYDIN | HYDIN, axonemal central pair apparatus protein |
907 | 1553468_at | HYDIN2 | HYDIN2, axonemal central pair apparatus protein (pseudogene) |
908 | 1553470_at | DNAH17 | dynein, axonemal, heavy chain 17 |
909 | 1553471_at | SLC35G3 | solute carrier family 35, member G3 |
910 | 1553472_at | LOC150596 | uncharacterized LOC150596 |
911 | 1553474_at | LOC100288966 | POTE ankyrin domain family member D-like |
912 | 1553475_at | NA | NA |
913 | 1553478_at | KIRREL3-AS3 | KIRREL3 antisense RNA 3 |
914 | 1553479_at | TMEM145 | transmembrane protein 145 |
915 | 1553482_at | C15orf32 | chromosome 15 open reading frame 32 |
916 | 1553483_at | TSGA10IP | testis specific, 10 interacting protein |
917 | 1553484_at | LINC00477 | long intergenic non-protein coding RNA 477 |
918 | 1553485_at | CCDC140 | coiled-coil domain containing 140 |
919 | 1553486_a_at | C17orf78 | chromosome 17 open reading frame 78 |
920 | 1553488_at | TEKT5 | tektin 5 |
921 | 1553489_a_at | TEKT5 | tektin 5 |
922 | 1553491_at | KSR2 | kinase suppressor of ras 2 |
923 | 1553492_a_at | PAX1 | paired box 1 |
924 | 1553493_a_at | TDH | L-threonine dehydrogenase (pseudogene) |
925 | 1553494_at | TDH | L-threonine dehydrogenase (pseudogene) |
926 | 1553497_at | LINC00615 | long intergenic non-protein coding RNA 615 |
927 | 1553498_at | NA | NA |
928 | 1553499_s_at | SERPINA9 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 |
- 928
- 3
Normal | Hypoxia | |
---|---|---|
1 | 0 | 1 |
2 | 0 | 1 |
3 | 1 | 0 |
4 | 1 | 0 |
Normal | Hypoxia | |
---|---|---|
Normal | 1 | 0 |
Hypoxia | 0 | 1 |
logFC | AveExpr | t | P.Value | adj.P.Val | B | |
---|---|---|---|---|---|---|
200958_s_at | 13.16920 | 13.11567 | 124.3121 | 4.891234e-07 | 2.954137e-05 | 5.351285 |
204006_s_at | 12.87494 | 12.61830 | 123.9542 | 4.936824e-07 | 2.954137e-05 | 5.350019 |
200748_s_at | 13.33368 | 13.34257 | 122.0398 | 5.190456e-07 | 2.954137e-05 | 5.343069 |
211919_s_at | 12.99841 | 12.80683 | 121.8356 | 5.218509e-07 | 2.954137e-05 | 5.342310 |
211742_s_at | 12.62507 | 12.33153 | 121.0488 | 5.328459e-07 | 2.954137e-05 | 5.339351 |
1555745_a_at | 12.85586 | 12.53620 | 121.0256 | 5.331751e-07 | 2.954137e-05 | 5.339263 |
AFFX-HSAC07/X00351_3_at | 12.84239 | 12.95069 | 120.9210 | 5.346613e-07 | 2.954137e-05 | 5.338865 |
AFFX-hum_alu_at | 13.11747 | 13.12849 | 120.9017 | 5.349360e-07 | 2.954137e-05 | 5.338792 |
212560_at | 12.62891 | 12.38139 | 120.4412 | 5.415465e-07 | 2.954137e-05 | 5.337029 |
217028_at | 13.12695 | 12.97323 | 120.2231 | 5.447149e-07 | 2.954137e-05 | 5.336188 |
208980_s_at | 12.53417 | 12.55008 | 120.1028 | 5.464738e-07 | 2.954137e-05 | 5.335722 |
202727_s_at | 12.53732 | 12.55374 | 119.9873 | 5.481680e-07 | 2.954137e-05 | 5.335273 |
202917_s_at | 13.44072 | 13.46929 | 119.8412 | 5.503220e-07 | 2.954137e-05 | 5.334704 |
200801_x_at | 12.79446 | 12.86409 | 119.7931 | 5.510328e-07 | 2.954137e-05 | 5.334517 |
200668_s_at | 12.48924 | 12.47371 | 119.5855 | 5.541183e-07 | 2.954137e-05 | 5.333703 |
201368_at | 12.71576 | 12.42925 | 119.5836 | 5.541462e-07 | 2.954137e-05 | 5.333696 |
212587_s_at | 12.65005 | 12.59432 | 119.5826 | 5.541612e-07 | 2.954137e-05 | 5.333692 |
202388_at | 12.95929 | 12.60095 | 119.3217 | 5.580716e-07 | 2.954137e-05 | 5.332665 |
200704_at | 12.84004 | 12.89974 | 119.2973 | 5.584377e-07 | 2.954137e-05 | 5.332569 |
200794_x_at | 12.66494 | 12.71327 | 119.1220 | 5.610873e-07 | 2.954137e-05 | 5.331874 |
215952_s_at | 12.73163 | 12.62020 | 118.9827 | 5.632039e-07 | 2.954137e-05 | 5.331321 |
209201_x_at | 12.96794 | 12.76079 | 118.9804 | 5.632398e-07 | 2.954137e-05 | 5.331311 |
AFFX-HSAC07/X00351_5_at | 12.36732 | 12.55121 | 118.8585 | 5.651011e-07 | 2.954137e-05 | 5.330826 |
201721_s_at | 13.02248 | 13.02379 | 118.8531 | 5.651844e-07 | 2.954137e-05 | 5.330804 |
224765_at | 12.35501 | 11.72387 | 118.6302 | 5.686084e-07 | 2.954137e-05 | 5.329912 |
228754_at | 12.34079 | 12.06019 | 118.5799 | 5.693850e-07 | 2.954137e-05 | 5.329710 |
AFFX-HSAC07/X00351_M_at | 12.53094 | 12.68500 | 118.5455 | 5.699171e-07 | 2.954137e-05 | 5.329572 |
208679_s_at | 12.82208 | 12.76857 | 118.4661 | 5.711483e-07 | 2.954137e-05 | 5.329252 |
204122_at | 12.78061 | 12.81913 | 118.3847 | 5.724132e-07 | 2.954137e-05 | 5.328923 |
211296_x_at | 12.73171 | 12.73269 | 118.3529 | 5.729075e-07 | 2.954137e-05 | 5.328795 |
⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ |
71 | 12.16112 | 11.66354 | 115.4135 | 6.212097e-07 | 2.954137e-05 | 5.316500 |
72 | 12.60173 | 12.61777 | 115.4121 | 6.212343e-07 | 2.954137e-05 | 5.316493 |
73 | 12.82313 | 13.02037 | 115.2926 | 6.233099e-07 | 2.954137e-05 | 5.315975 |
74 | 12.35619 | 11.88091 | 115.2806 | 6.235184e-07 | 2.954137e-05 | 5.315923 |
75 | 12.01287 | 11.82985 | 115.2349 | 6.243133e-07 | 2.954137e-05 | 5.315725 |
76 | 12.08655 | 11.76656 | 115.1775 | 6.253161e-07 | 2.954137e-05 | 5.315475 |
77 | 12.08300 | 11.74270 | 115.1515 | 6.257710e-07 | 2.954137e-05 | 5.315361 |
78 | 13.05271 | 13.04967 | 115.0145 | 6.281731e-07 | 2.954137e-05 | 5.314763 |
79 | 12.08619 | 11.89104 | 114.9890 | 6.286219e-07 | 2.954137e-05 | 5.314652 |
80 | 12.63099 | 12.73537 | 114.9662 | 6.290222e-07 | 2.954137e-05 | 5.314552 |
81 | 12.04174 | 12.15283 | 114.9463 | 6.293735e-07 | 2.954137e-05 | 5.314465 |
82 | 12.28123 | 12.27198 | 114.9459 | 6.293805e-07 | 2.954137e-05 | 5.314463 |
83 | 12.36272 | 12.52576 | 114.9123 | 6.299725e-07 | 2.954137e-05 | 5.314316 |
84 | 12.09863 | 11.61412 | 114.8484 | 6.311019e-07 | 2.954137e-05 | 5.314035 |
85 | 12.11993 | 12.16425 | 114.7207 | 6.333660e-07 | 2.954137e-05 | 5.313474 |
86 | 12.14712 | 11.62236 | 114.6764 | 6.341531e-07 | 2.954137e-05 | 5.313279 |
87 | 12.16596 | 12.04887 | 114.6760 | 6.341598e-07 | 2.954137e-05 | 5.313277 |
88 | 12.07946 | 12.06161 | 114.6299 | 6.349816e-07 | 2.954137e-05 | 5.313074 |
89 | 11.99899 | 12.09922 | 114.6182 | 6.351897e-07 | 2.954137e-05 | 5.313022 |
90 | 11.92110 | 11.82842 | 114.6063 | 6.354027e-07 | 2.954137e-05 | 5.312970 |
91 | 12.19644 | 12.19601 | 114.5656 | 6.361297e-07 | 2.954137e-05 | 5.312790 |
92 | 12.22030 | 12.22629 | 114.5647 | 6.361456e-07 | 2.954137e-05 | 5.312786 |
93 | 12.28066 | 12.24067 | 114.5480 | 6.364439e-07 | 2.954137e-05 | 5.312712 |
94 | 12.13352 | 12.16809 | 114.5474 | 6.364545e-07 | 2.954137e-05 | 5.312709 |
95 | 12.04900 | 11.96460 | 114.5259 | 6.368395e-07 | 2.954137e-05 | 5.312614 |
96 | 12.27975 | 12.26686 | 114.4355 | 6.384589e-07 | 2.954137e-05 | 5.312214 |
97 | 12.19763 | 12.27570 | 114.4078 | 6.389574e-07 | 2.954137e-05 | 5.312091 |
98 | 12.86782 | 13.04416 | 114.4035 | 6.390343e-07 | 2.954137e-05 | 5.312072 |
99 | 12.04219 | 11.50384 | 114.3701 | 6.396356e-07 | 2.954137e-05 | 5.311924 |
100 | 12.72957 | 12.72944 | 114.3418 | 6.401459e-07 | 2.954137e-05 | 5.311798 |
- 100
- 6
Step 6:
PCA is a mathematical algorithm that reduces the dimensionality of the data while retaining most of the variation in the data set. It does so by identifying directions, called principal components, along which the variation in the data is maximal. PCA plots check whether the overall variability of the samples reflect their groupings.
The two PCA plots show that the gene expressions of the neutrophils under the two conditions do vary. This is clear on the plots as the points for the two hypoxia samples are on right side of the plot, whereas the two normal samples are found on the left of the plot. It is unclear whether there is a clear difference between the gene expressions of the two sample groups themselves; in order to observe a clear difference between samples, more conditions are required, such as different levels of hypoxia.
Step 7:
Heat maps and clustering are often used in gene expression analysis studies to visualise the data and for quality control. It is a graphical representation of the data where the individual values in the matrix are represented as colours. They compares the level of gene expression of a number of samples, allowing for immediate visualisation of the data by assigning different colours to each gene, and it is possible to see clusters of genes with similar or hugely different expression values.
The heatmaps above are generated from eset_rma and eset_puma data, both showing similar patterns of gene expression, as indicated by the colours. From both methods, it can be deduced that a lot of genes that are expressed in samples order normal conditions are not expressed in samples under hypoxia, confirming that hypoxia has an effect on neutrophil gene expression.
Step 8:
This step involves the functional/ pathway analysis of differentially expressed targets using PANTHER or DAVID. DAVID is the online Database for Annotation, Visualization and Integrated Discovery, which can be used to convert a list of gene IDs. PANTHER (Protein ANalysis THrough Evolutionary Relationships) can be used to classify proteins and identify the key pathways involved in the difference in gene expression observed. PANTHER is used in this project to identify the key pathways in regulating gene expression in neutrophils under hypoxia and normal conditions.
V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | V9 | V10 |
---|---|---|---|---|---|---|---|---|---|
1 | Axon | guidance | mediated | by | Slit/Robo | (P00008) | 1 | 1.1% | 1.6% |
2 | JAK/STAT | signaling | pathway | (P00038) | 1 | 1.1% | 1.6% | ||
3 | Axon | guidance | mediated | by | semaphorins | (P00007) | 1 | 1.1% | 1.6% |
4 | p38 | MAPK | pathway | (P05918) | 1 | 1.1% | 1.6% | ||
5 | Interleukin | signaling | pathway | (P00036) | 4 | 4.5% | 6.3% | ||
6 | Angiogenesis | (P00005) | 1 | 1.1% | 1.6% | ||||
7 | Interferon-gamma | signaling | pathway | (P00035) | 1 | 1.1% | 1.6% | ||
8 | Alzheimer | disease-presenilin | pathway | (P00004) | 2 | 2.3% | 3.1% | ||
9 | Integrin | signalling | pathway | (P00034) | 5 | 5.7% | 7.8% | ||
10 | Inflammation | mediated | by | chemokine | and | cytokine | signaling | pathway | (P00031) |
9 | 10.2% | 14.1% | |||||||
11 | Ubiquitin | proteasome | pathway | (P00060) | 1 | 1.1% | 1.6% | ||
12 | Angiotensin | II-stimulated | signaling | through | G | proteins | and | beta-arrestin | (P05911) |
1 | 1.1% | 1.6% | |||||||
13 | Endothelin | signaling | pathway | (P00019) | 1 | 1.1% | 1.6% | ||
14 | EGF | receptor | signaling | pathway | (P00018) | 1 | 1.1% | 1.6% | |
15 | Gonadotropin-releasing | hormone | receptor | pathway | (P06664) | 2 | 2.3% | 3.1% | |
16 | DNA | replication | (P00017) | 2 | 2.3% | 3.1% | |||
17 | PDGF | signaling | pathway | (P00047) | 3 | 3.4% | 4.7% | ||
18 | Cytoskeletal | regulation | by | Rho | GTPase | (P00016) | 3 | 3.4% | 4.7% |
19 | Oxidative | stress | response | (P00046) | 1 | 1.1% | 1.6% | ||
20 | Ras | Pathway | (P04393) | 1 | 1.1% | 1.6% | |||
21 | Nicotinic | acetylcholine | receptor | signaling | pathway | (P00044) | 1 | 1.1% | 1.6% |
22 | Cadherin | signaling | pathway | (P00012) | 2 | 2.3% | 3.1% | ||
23 | Blood | coagulation | (P00011) | 1 | 1.1% | 1.6% | |||
24 | B | cell | activation | (P00010) | 2 | 2.3% | 3.1% | ||
25 | CCKR | signaling | map | (P06959) | 4 | 4.5% | 6.3% | ||
26 | Huntington | disease | (P00029) | 3 | 3.4% | 4.7% | |||
27 | Heterotrimeric | G-protein | signaling | pathway-Gq | alpha | and | Go | alpha | mediated |
pathway | (P00027) | 2 | 2.3% | 3.1% | |||||
28 | Wnt | signaling | pathway | (P00057) | 1 | 1.1% | 1.6% | ||
29 | Heterotrimeric | G-protein | signaling | pathway-Gi | alpha | and | Gs | alpha | mediated |
pathway | (P00026) | 1 | 1.1% | 1.6% | |||||
30 | Glycolysis | (P00024) | 1 | 1.1% | 1.6% | ||||
31 | Toll | receptor | signaling | pathway | (P00054) | 1 | 1.1% | 1.6% | |
32 | T | cell | activation | (P00053) | 2 | 2.3% | 3.1% | ||
33 | FGF | signaling | pathway | (P00021) | 1 | 1.1% | 1.6% |
From PANTHER, the gene list and the pathways they work in have been identified, with the piechart showing the percentage of genes that are present in each pathway. The most prominent pathway in the effects of hypoxia on human neutrophils is identified as the Inflammation mediated by chemokine and cytokine signaling pathway.
Discussion
In this project, the aim was to stimate gene expression levels, and analyse the results to identify the genes that are changing between the two conditions of normal and hypoxia, defining the potential pathways that hypoxia may have altered in neutrophils. The methods of RMA and MAS5 were used, and first diagnostics performed in order to identify the suitable method to continue with. RMA was chosen as no further normalisation was required. The PUMA package was also used, and the data combined using a Bayesian Hierarchical model, further analysis was done in order to obtain the fold change in gene expression. Limma was used for Differential Expression Analysis, and the p-value calculated. The data was visualised using PCA, indicating that there is a clear difference between the gene expression of neutrophils under normal, or hypoxia conditions. This was further supported by the heatmaps generated.
Through the use of PANTHER, it was possible to identify the key pathways that are regulating the effects of hypoxia on human neutrophils - The Inflammation mediated by chemikine and cytokine signaling pathway.
References
https://www.bioconductor.org/packages/devel/bioc/vignettes/puma/inst/doc/puma.pdf https://www.bioconductor.org/packages/devel/bioc/manuals/puma/man/puma.pdf https://www.bioconductor.org/packages/release/bioc/vignettes/affy/inst/doc/affy.pdf http://svitsrv25.epfl.ch/R-doc/library/Biobase/html/00Index.html#P http://bioinfo.cipf.es/babelomicstutorial/maplot http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/Help/3 Visualisation/3.2 Figures and Graphs/3.2.13 The MA Plot.html https://www.biostars.org/p/101727/ http://www.nature.com/ng/journal/v32/n4s/pdf/ng1032.pdf http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-103 http://www.nature.com/nbt/journal/v26/n3/pdf/nbt0308-303.pdf http://wiki.bits.vib.be/index.php/Analyze_your_own_microarray_data_in_R/Bioconductor#MA_plots http://arrayanalysis.org/main.html